Vaccinations and testing are both critical for a fast and safe reopening of the US economy. But testing at scale is still in its infancy, and there is a steep learning curve for how to do it cost-effectively.
This was the topic of conversation at the first LinkedIn Live panel I hosted with Dr. Michael Mina and Professor Ajay Agrawal, leaders working with Genpact on the Rapid Action Consortium, a collective effort that supports scaling the use of rapid antigen testing, particularly in the workplace.
Dr. Mina, an epidemiologist at Harvard University, and Professor Agrawal, founder of the Creative Destruction Lab and professor at the Rotman School of Management, both sit on the consortium's advisory committee. We discussed the evidence behind the continuing need for widespread testing.
Here are three major takeaways from our conversation.